Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
